ArticleBMC cancer2020

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.

John Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.